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Central aortic pressure augmentation in stable renal
transplant recipients
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Central aortic pressure augmentation in stable renal transplant ure [1]. Thus, better management of cardiovascular dis-
recipients. ease and its risk factors potentially could improve both
Background. Premature cardiovascular disease is the lead- recipient and graft survival. However, despite the abun-ing cause of death in renal transplant recipients and classical
dance of evidence relating to the management of cardio-risk factors significantly underestimate the risk. The increased
vascular risk in the non-renal population, the evidenceeffect of arterial wave reflections on central arteries has re-
cently been shown to be an important independent predictor of base available for the rational management of cardiovas-
cardiovascular mortality in chronic hemodialysis patients. The cular risk in renal transplant recipients is small.
aim of this study was to assess the contribution of several Enhanced augmentation of the central aortic systolic
classical and potential non-classical cardiovascular risk factors
pressure by the increased effect of arterial wave reflec-on aortic pressure augmentation by the reflected arterial wave
tions, as defined by the augmentation index (AIx), hasin stable renal transplant recipients.
recently been shown to be a powerful predictor of cardio-Methods. Using the non-invasive technique of pulse wave
analysis aortic augmentation was investigated in 250 stable vascular and all cause mortality in patients on chronic
renal transplant recipients. Peripheral pulse waveforms were hemodialysis (Fig. 1) [2]. The technique of central pulse
recorded from the radial artery. Central aortic waveforms were wave analysis employs applanation tonometry to recordthen generated and the aortic augmentation index calculated.
the pressure wave from the radial artery accurately [3],Results. In multivariate analysis, female sex (regression coef-
and a well-validated generalized transfer factor can thenficient 7.5  1.7%; P  0.001), heart rate (4.8  0.5% per
10 beats/min; P  0.001), mean arterial pressure (4.2  0.6% be used to generate the corresponding aortic arterial
per 10 mm Hg; P  0.001), the persistence of an arteriovenous waveform [4]. From this, AIx can be assessed non-inva-
fistula (4.1 1.3%; P 0.005), total time on renal replacement sively and reproducibly [5, 6].
therapy (3.8  0.9% per 10 years; P  0.001), height (3.1  Classical risk factors do not account for the totality0.8% per 10 cm; P  0.001), immunosuppression with cyclo-
of cardiovascular risk in renal transplant recipients. Asporine (2.8  1.3%; P  0.005) and age (2.5  0.5% per
recent study found that the Framingham Heart Study-10 years; P  0.001) were all important correlates of aortic
augmentation index. based cardiovascular risk equation significantly under-
Conclusions. Our findings suggest, to our knowledge for the estimated the risk of ischemic heart disease in renal trans-
first time, that both the presence of a functioning arteriovenous plant recipients [7]. These findings suggest that other
fistula and immunosuppressive treatment with cyclosporine are factors, in particular non-classical cardiovascular riskassociated with an increased aortic augmentation index in re-
factors, may play a significant role in the increased car-nal transplant recipients and could, therefore, be potential re-
diovascular risk observed in these patients. Identificationversible contributors to the high cardiovascular risk profile in
these patients. of these non-classical risk factors might help target inter-
ventions to reduce the high incidence of cardiovascular
events observed in renal transplant recipients. The aim
of this study was to assess the impact of several classicalPremature cardiovascular disease is the leading cause
cardiovascular risk factors, immunosuppressive agents,of death in renal transplant recipients and as a conse-
renal function and the presence of an arteriovenousquence, one of the leading causes of renal allograft fail-
(A-V) fistula on AIx in a large cohort of stable renal
transplant recipients.
Key words: arterial wave reflection, kidney transplant, calcineurin in-
hibitors, arteriovenous fistula, cardiovascular disease.
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aortic pressure. AIx represents the difference between
the first and second peaks of the central pressure wave-
form in systole (Fig. 1), expressed as a percentage of the
pulse pressure. Values are reported as the mean of two
stable readings.
Data analysis
Statistical analysis was performed with SPSS version
8.0 for windows (SPSS Inc, Chicago, IL, USA). A multi-
ple linear regression model was derived for AIx using
stepwise regression analysis. Factors introduced into the
model were sex, age, height, weight, heart rate, mean
blood pressure, left ventricular ejection time (LVET),
smoking and diabetic history, presence of a functioning
A-V fistula, immunosuppression with cyclosporine, tacro-
limus or a non-calcineurin inhibitor based regime, anti-
hypertensive and cholesterol lowering medication, serum
total cholesterol, albumin, calcium and phosphate con-
Fig. 1. Representative aortic waveform. There are two distinct peaks centrations, hemoglobin concentration, calculated creat-
during systole (1 and 2). Augmentation index (AIx) is defined as the inine clearance, months from current transplant and total
difference between the second and the first systolic peaks (P), ex-
time on renal replacement therapy. Factors that werepressed as a percentage of the pulse pressure. The first inflection point
(1) indicates the return of the reflected wave (Tr). not significant were excluded from the model. The final
model was checked for normality by plotting the residu-
als. Results are means standard deviations or medians
(interquartile ranges). Normally distributed variables
changed by more than 5 mL/min for at least three months were analyzed by unpaired t tests or analysis of variance
were recruited from the transplant clinics at the Richard (ANOVA). Variables that were not normally distributed
Bright Kidney Unit, Southmead Hospital, Bristol. Ap- were analyzed by Mann-Whitney U or Kruskal-Wallis
proval for the study was obtained from the local Re- non-parametric tests. Frequency differences were tested
search Ethics Committee and informed consent obtained by the 2 test. A P value of0.05 was considered statisti-
from each participant. The investigation conformed to cally significant.
the principles outlined in the Declaration of Helsinki.
Peripheral blood pressure measurement RESULTS
Brachial artery blood pressure was measured in du- Two subjects were excluded from the analysis because
plicate using a validated oscillometric technique (HEM- of incomplete data being available. Both cases were
705CP; Omron) [8] or using a mercury sphygmomano- wheelchair bound and, therefore, their height could not
meter according to the recommendations of the British be accurately measured. Inclusion of these two patients
Hypertension Society [9]. Values are reported as the by estimating their height did not make any significant
mean of two stable readings. impact on the analysis. The demographics of the group
are shown in Tables 1 and 2 with patients divided by
Pulse wave analysis persistence of arteriovenous (AV) fistula and immuno-
Central pressure waveforms were derived and ana- suppressive regime, respectively. All but two of the pa-
lyzed using the technique of pulse wave analysis (Sphyg- tients taking cyclosporine were on the Neoral formula-
moCor; PWV Medical, Sydney, Australia) as previously tion (Novartis, Surrey, UK).
described [5, 6, 10]. In brief, a high fidelity micromano- In multivariate analysis, gender, heart rate, mean arte-
meter (SPC-301; Millar Instruments, TX, USA) was used rial pressure (MAP), the presence of a functioning A-V
by an experienced operator (CJF) to flatten, but not oc- fistula, total time on renal replacement therapy, height,
clude, the radial artery by using gentle pressure with the use of cyclosporine in the immunosuppressive regime
wrist slightly extended and supported on a pillow. Data and age were important correlates of AIx (Table 3).
were collected directly into a portable computer and, Together these variables accounted for 60% of the vari-
after 11 seconds of data capture, an averaged peripheral ance. The mean values for AIx in patients with and
waveform and a corresponding central waveform were without a persistent AV fistula and on different immuno-
generated. The central waveform was then analyzed us- suppression regimes are shown in Figure 2. Diabetes,
creatinine clearance, albumin, hemoglobin, smoking his-ing the system software to determine AIx and central
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Table 1. Characteristics of renal transplant recipients according to the presence or absence of a functioning anteriovenous (AV) fistula
Male Female
Fistula No fistula Fistula No fistula
(N  58) (N  100) (N  31) (N  59)
Age years 5112 4714 5112 4715
Height m 1758 1757 1637 1627
Current transplant months (range) 43 (20–94)a 77 (39–128) 42 (13–92)a 63 (3–108)
Time on RRT months (range) 95 (43–174) 107 (6–168) 124 (35–146) 97 (60–66)
Diabetic % 4 (7) 10 (10) 4 (13) 9 (15)
Smoking history % 9 (16) 14 (14) 1 (3) 6 (10)
On cyclosporin % 21 (36) 61 (61) 17 (55) 38 (64)
On tacrolimus % 30 (52)a 18 (18) 11 (35) 12 (20)
Number on statins % 15 (26) 32 (32) 11 (36) 22 (37)
Number of antihypertensives 1.91.0 2.11.0 2.11.1 1.91.2
Hemoglobin g/dL 13.41.2 13.51.6 12.32.3 11.91.7
CCr ml/min 5219 5619 4321 4620
Brachial SBP mm Hg 14417a 13715 13818 14117
Brachial DBP mm Hg 8310 8410 8112 858
Heart rate beats/min 6812 6613 6816 6512
Aortic SBP mm Hg 12916 12416 12818 13218
Aortic DBP mm Hg 8412 8510 8112 868
Tr ms 14214a 14714 13114a 13916
Data are means  SD, medians (first and third quartiles), N (%). Abbreviations are: RRT, renal replacement therapy; CCr, creatinine clearance; SBP, systolic
blood pressure; DBP, diastolic blood pressure; Tr, timing of return of reflected wave.
a P  0.05 for fistula versus no fistula in both males and female patients
Table 2. Characteristics of renal transplant recipients according to immunosuppressive regime
Cyclosporine Tacrolimus Other
Male Female Male Female Male Female
(91) (55) (39) (23) (28) (12)
Age years 5014 5212 4715 3611 4811 5213
Height m 1758 1616 1757 1649 1767 1646
Current transplant
months (range) 73 (44–105) 63 (39–104) 22c (14–41) 23a (11–60) 180c (11–-227) 192a (84–241)
Total time on RRT
months (range) 106 (65–147) 60 (96–156) 46c (30–108) 84c (23–144) 191c (125-277) 200c (91–253)
Fistula % 30 (33) 17 (31) 21 (54) 11 (48) 7 (25) 3 (25)
Hemoglobin g/dL 13.31.5 12.01.8 13.81.9 12.62.4 13.31.6 11.71.4
CCr mL/min 5619 4118 5414 5521a 5424 4123
Total cholesterol g/dL 5.11.0 5.41.0 4.80.9 4.90.9 4.70.9 5.51.2
Brachial SBP mm Hg 14016 14319 13917 13217 13816 13810
Brachial DBP mm Hg 8410 8410 8312 8310 839 825
Heart rate beats/min 6513 6513 7112 7216 6511 6212
Aortic SBP mm Hg 12716 13519 12217 12016b 12618 1319
Aortic DBP mm Hg 8510 8510 8413 8410 849 835
Diabetes % 11 (12) 10 (18) 6 (15) 3 (13) 2 (7) 0
Smoker % 12 (13) 5 (9) 5 (13) 3 (13) 1 (4) 1 (8)
Number on statins % 27 (30) 25 (46) 9 (23) 3 (13) 11 (39) 5 (42)
Number of antihypertensives 2.01.1 2.01.1 1.90.9 2.31.1 2.21.2 1.41.1
Tr ms 14615 13415 14513 14317 14413 13614
Data are means  SD, medians (first and third quartiles), N (%). Abbreviations are: RRT, renal replacement therapy; CCr, creatinine clearance; SBP, systolic
blood pressure; DBP, diastolic blood pressure; Tr, timing of return of reflected wave.
a P  0.05, b P  0.01, c P  0.0001 for patients in the tacrolimus or non-calcineurin inhibitor based immunosuppression groups versus patients in the cyclosporine
group
tory, weight, total cholesterol level, calcium phosphate apy was not included in the model, time from current
product, LVET and use of antihypertensive or lipid low- transplant became an independent predictor of variation
ering medication were not significant determinants. Re- in AIx (coefficient 4.8 1.0%; P 0.001) with the other
sults for the coefficients in the equation (Table 3) are correlates remaining unchanged.
expressed in clinically meaningful units of measurement.
Time from current transplant was excluded from the final
DISCUSSIONmodel using stepwise regression, most likely because of
The results show that three non-classical risk factorsits correlation with time on renal replacement therapy
(r  0.76, P 0.0001). If time on renal replacement ther- for cardiovascular disease—the persistence of an A-V
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Table 3. Multiple linear regression analysis with augmentation
index as the dependent variable
Regression Standard
Variable Units coefficient error P value
Gender Female 7.5 1.7 0.001
Heart rate 10 bpm 4.8 0.5 0.001
MAP 10 mm Hg 4.2 0.6 0.001
A-V fistula Persistent 4.1 1.3 0.005
Time on RRT 10 years 3.8 0.9 0.001
Height 10 cm 3.1 0.8 0.001
Cyclosporine Yes 2.8 1.3 0.005
Age 10 years 2.5 0.5 0.001
Adjusted R2 value for the entire study group, 0.6, P  0.001. Abbreviations
are: bpm, beats per minute; MAP, brachial mean arterial pressure; AV, arterio-
venous; RRR, renal replacement therapy.
fistula, time on renal replacement therapy and treatment
with cyclosporine—are important contributors to AIx.
In addition to these factors, our study confirmed that
gender, heart rate, blood pressure, height and age remain
important determinants of AIx in renal transplant recipi-
ents. The contribution made by these factors to AIx is
very similar to that observed in healthy subjects [11]. In-
deed, an increase of 10 beats per minute in heart rate
in our study produced a decrease in AIx of 5%, which is
very similar to the percentage found in an interventional
study using patients with cardiac pacemakers in which
AIx decreased by 4% for every 10 beats per minute
increase in heart rate [12].
Augmentation index is often considered to be an index
of arterial stiffening. However, AIx depends on many
factors including pulse wave velocity, traveling distance
of pressure waves (body height), ejection duration, and
the reflective properties of the arterial system. Arterial
stiffening increases pulse wave velocity and influences
transit times of pressure waves (Tr in Fig. 1). Arterial stiff-
ening, therefore, reduces Tr from the peripheral reflec- Fig. 2. (A) Augmentation index in women (shaded) and men (striped)
tive sites toward the ascending aorta, thereby altering with and without a functioning arteriovenous fistula. (B) Augmentation
index in women (shaded) and men (striped) on cyclosporine, tacrolimusthe timing of incident and reflective waves. The intensity
or on a non-calcineurin–inhibitor based immunosuppressive regimeof wave reflection is dependent on the reflective proper- (*P  0.01 ANOVA).
ties of the vascular tree that could be altered indepen-
dently of vascular stiffening [13]. The peripheral reflec-
tance is influenced by physical properties, vasomotor tone
also results in decreased diastolic tension-time indexand the number of smaller resistance arteries [13]. Sev-
[15, 17]. These alterations increase left ventricular oxy-eral abnormalities in the microcirculation of renal failure
gen requirements and predisposes to left ventricular hy-patients have been reported including decreased endo-
pertrophy. The reduced diastolic tension-time index con-thelium-mediated vasodilation in cyclosporine-treated
tributes to modifications of coronary perfusion withtransplant recipients [14]. Using pulse wave analysis, it
relative subendocardial ischemia [15, 18]. Therefore, itis currently not possible to distinguish the relative contri-
is perhaps not surprising that AIx has been found tobutions made by large or small vessel pathology to the
have a strong association with echographically measuredmeasured AIx.
left ventricular hypertrophy [10] and has been found toAn increased effect of wave reflections on the aorta
be a powerful predictor of cardiovascular and all-causecauses increased pressure during systole increasing left
mortality in hemodialysis treated patients [2].ventricular workload and promoting left ventricular hy-
We found the persistence of a functioning A-V fistulapertrophy [15], a strong independent predictor for all-
cause mortality [16]. Early return of the reflected wave to be associated with a higher AIx in this population.
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The creation of an AV fistula for hemodialysis access responsible for the increased AIx observed in the cyclo-
sporine treated patients in our study. Interestingly, therelowers systemic vascular resistance and results in an in-
crease in cardiac output in order to maintain blood pres- was no significant difference in Tr between patients on
cyclosporine and tacrolimus, suggesting that the in-sure [19]. A sustained increase in cardiac output and
arterial flow is associated with dilation and hypertrophy creased AIx observed in cyclosporine treated patients is
not as a consequence of increased aortic stiffness.of large conduit arteries [20]. Moreover, a persistent
increase in cardiac output, by the mechanism of myo- Although cyclosporine and tacrolimus are both cal-
cineurin inhibitors and are thought to have similar intrin-genic autoregulation of peripheral blood flows, can lead
to a secondary increase in peripheral resistances and sic properties, the incidence of hypertension has been
found to be lower in patients treated with tacrolimusremodeling of small resistance arteries [21]. These alter-
ations in vascular structure and function have a negative compared with cyclosporine treated patients [27]. How-
ever, trough tacrolimus levels strongly correlate with totalfeedback on left ventricular afterload, increasing the aor-
tic impedance [22]. The enlargement of large conduit tacrolimus exposure, whereas this correlation is poor for
cyclosporine [28]. Thus, it may be easier to stay withinarteries increases the inertial effect of the blood mass,
the hypertrophy of arterial walls increases the stiffness the therapeutic target for tacrolimus, which may trans-
late into less post-transplant hypertension and arterialof the arteries, and the remodeling of the resistance
arteries increases the peripheral resistance. These effects stiffness. All except two of the patients in this study
were on the Neoral formulation of cyclosporine, whichserve to increase AIx, as observed in our study. Further-
more, these changes in circulatory hemodynamics lead contains -tocopherol. From our study we cannot tell
whether this antioxidant vitamin affects arterial stiffnessto left ventricular hypertrophy as an adaptive response
to a long-term increase in volume and pressure overload. in any way. Patients not on a calcineurin inhibitor-based
immunosuppressive regime (all were on steroids and aza-Indeed, left ventricular mass decreases significantly in
renal transplant patients after closure of an AV fistula thioprine or mycophenolate mofetil) had similar AIx to
patients on cyclosporine. However, these patients hadwith no observed change in blood pressure [23]. Whether
AIx would decrease, or indeed cardiovascular risk im- been on renal replacement therapy for a considerably
longer period of time (Table 2), which we have shownprove after closure of an AV fistula is still to be deter-
mined. However, rather intriguingly, the presence of a to increase AIx. In our cohort, patients would have been
on tacrolimus only if they had a mismatch at the DRprevious AV fistula has been found to be associated with
fatal and nonfatal cardiac events perioperatively during locus, on a second or subsequent transplant, or had an
episode of rejection while on the cyclosporine treatment.the AV fistula creation [24], suggesting that the presence
of an AV fistula is indeed a non-classical cardiovascular Although we believe it to be unlikely, it is possible that
any of these factors could in some way account for therisk factor.
Hypertension occurs in approximately 80% of patients increased AIx observed in patients on cyclosporine com-
pared to those on tacrolimus.on cyclosporine following renal transplantation [25]. Us-
ing multivariate analysis to correct for blood pressure, Diabetes mellitus has been shown to increase AIx in
some [29, 30], but not all [31] studies. It appears thatwe found cyclosporine—but not tacrolimus—to be asso-
ciated with a higher AIx, despite both agents being cal- any effects of diabetes mellitus may have been masked
by the other factors relating to this cohort. Furthermore,cineurin inhibitors and being thought of as having similar
actions. Indeed, compared with patients on tacrolimus, only 10% of our cohort had diabetes mellitus (Table 2),
and any small effect may have been missed. Creatininepatients on cyclosporine had a markedly raised AIx
(Fig. 2). Cyclosporine also has been found to predispose clearance was not associated with AIx in our group of
patients. Creatinine clearance has been shown to be asso-to left ventricular hypertrophy more so than would be
expected from the higher associated blood pressure [26], ciated with arterial stiffness but only in subjects with
plasma creatinine concentrations well within the normala finding that could be explained, at least in part, by the
association we have found between cyclosporine treat- range [32]. From our study it would appear that length
of exposure to uremia is a much more important factorment and higher AIx.
The pathophysiology of cyclosporine-induced hyper- than renal function after transplantation. Neither total
serum cholesterol nor treatment with a statin was associ-tension is not yet known. Several possible mechanisms
have been proposed including sodium retention, raised ated with AIx in this study. Although increased arterial
stiffness has been shown in hypercholesterolemics [33],circulating endothelin levels, transforming growth fac-
tor- (TGF-) mediated endothelin synthesis, altered most of our study population had a total cholesterol
value within the normal range (Table 2) and thus anyprostaglandin production, impaired basal production of
nitric oxide, increased plasma renin activity and activa- small interaction may have been missed. Similarly, hy-
perparathyroidism has been associated with increasedtion of the sympathetic nervous system [14]. It seems
likely that one or more of these mechanisms may be AIx [34], but most of our patients had calcium phosphate
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heart rate on augmentation index and central arterial pressure inproducts within the normal range. Not enough patients
humans. J Physiol 525:263–270, 2000
in this study had their serum parathyroid hormone as- 13. Glasser SP, Arnett DK, McVeigh GE, et al: Vascular compliance
and cardiovascular disease: A risk factor or marker? Am J Hyper-sayed for any meaningful statistical analysis to be per-
tens 10:1175–1189, 1997formed.
14. Morris STW, McMurray JJV, Rodger RSC, et al: Endothelial
In conclusion, we have found that both having a func- dysfunction in renal transplant recipients maintained on cyclospo-
rine. Kidney Int 57:1100–1106, 2000tioning A-V fistula and being on cyclosporine are associ-
15. O’Rourke MF, Kelly RP: Wave reflection in the systemic circula-ated with having a higher AIx and, therefore, are poten- tion and its implications in ventricular function. J Hypertens 11:327–
tially treatable factors that if addressed could result in 337, 1993
16. Levy D, Garrison RJ, Savage DD, et al: Prognostic implicationslower cardiovascular morbidity and mortality in this high
of echocardiographically determined left ventricular mass in therisk population. Longitudinal studies are needed to show Framingham heart study. N Engl J Med 322:1561–1566, 1990
whether these factors are indeed non-classical cardiovas- 17. Nicholls WW, O’Rourke MF: McDonald’s Blood Flow in Arter-
ies: Theoretical, Experimental and Clinical Principles (4th ed). Lon-cular risk factors.
don, Edward Arnold, 1988
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